Gemcitabine-induced programmed cell death (apoptosis) of human pancreatic carcinoma is determined by bcl-2 content

Annals of Surgical Oncology

Volumn 6, Issue 3, 1999, Pages 279-285

  Bold, Richard J ^a,b   Chandra, Joya ^a   McConkey, David J ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Apoptosis; Bcl 2; Gemcitabine; Pancreatic cancer

Indexed keywords

GEMCITABINE; PROTEIN BCL 2;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; HUMAN; HUMAN CELL; INOPERABLE CANCER; ONCOGENE; PANCREAS CARCINOMA; PROTEIN CONTENT;

EID: 0032921777     PISSN: 10689265     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10434-999-0279-x     Document Type: Article

References (24)

1. Fernandez E, La Vecchia C, Porta M, et al. Trends in pancreatic cancer mortality in Europe, 1955-1989. Int J Cancer 1994;57:786-92.
2. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1996. CA Cancer J Clin 1996;46:5-27.
3. Williamson RC. Pancreatic cancer: the greatest oncological challenge. Br Med J 1988;296:445-6.
4. Gordis L, Gold EB. Epidemiology of pancreatic cancer. World J Surg 1984;8:808-21.
5. Abbruzzese JL, Grunewald R, Weeks EA, et al. A phase 1 clinical, plasma and cellular pharmacology study of gemcitabine. J Clin Oncol 1991;9:491-8.
6. Casper ES, Green MR, Kelsen DP, et al. Phase II trial of gemcitabine (2′,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 1994;12:29-34.
7. Moore M, Andersen J, Burris H, et al. A randomized trial of gemcitabine versus 5-FU as first-line therapy in advanced pancreatic cancer [Abstract]. Proc Am Soc Clin Oncol 1995;14:199.
8. White E. Life, death and the pursuit of apoptosis. Genes Dev 1996;10:1-15.
9. Kerr JFR, Winterford CM, Harmon BV. Apoptosis: its significance in cancer and cancer therapy. Cancer 1994;73:2013-26.
10. McConkey DJ, Greene G, Pettaway CA. Apoptosis resistance increases with metastatic potential in cells of the human LNCaP prostate carcinoma line. Cancer Res 1996;56:5594-9.
11. Krajewski S, Thor AD, Edgerton SM, et al. Analysis of Bax and Bcl-2 expression in p53-immunopositive breast cancers. Clin Cancer Res 1997;3:199-208.
12. Brambilla E, Negoescu A, Gazzeri S, et al. Apoptosis-related factors p53, Bcl-2, and Bax in neuroendocrine lung tumors. Am J Pathol 1996;149:1941-52.
13. Sinicrope FA, Ruan SB, Cleary KR, et al. Bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Res 1995;55:237-41.
14. Meyn RE, Stephen LC, Milas L. Programmed cell death and radioresistance. Cancer Metastasis Rev 1996;15:119-31.
15. Reed JC. Regulation of apoptosis by Bcl-2 family proteins and its role in cancer and chemoresistance. Curr Opin Oncol 1995;7: 541-6.
16. Hickman JA. Apoptosis and chemotherapy resistance. Eur J Cancer 1996;32A:921-6.
17. Kanada M, Aime-Sempe C, Sato T, Reed JC. Structure-function analysis of Bcl-2 protein: identification of conserved domains important for homodimerization with Bcl-2 and heterodimerization with Bax. J Biol Chem 1995;270:11962-9.
18. Denizot F, Lang R. Rapid colorimetric assay for cell growth and survival: modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Methods 1986;22: 271-7.
19. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991;139:271-9.
20. Introduction of recombinant vectors into mammalian cells. In: Sambrook J, Fritsch EF, Maniatis T, eds. Molecular cloning: a laboratory manual, 3rd ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1995:16.30-6.
21. Lee WY, Jin YT, Tzeng CC. Reciprocal expression of Bcl-2 and p53 in breast ductal carcinoma. Anticancer Res 1996;16:3007-12.
22. Kapranos N, Karaiosifidi H, Valavanis C, Kouri E, Vasilaros S. Prognostic significance of apoptosis related proteins Bcl-2 and Bax in node-negative breast cancer patients. Anticancer Res 1997;17: 2499-505.
23. Matsushima H, Kitamura T, Goto T, Hosaka Y, Homma Y, Kawabe K. Combined analysis with Bcl-2 and p53 immunostaining predicts poorer prognosis in prostatic carcinoma. J Urol 1997;158: 2278-83.
24. Sinicrope FA, Evans DB, Leach SD, Cleary KR, Fenoglio CJ, Lee JJ, Abbruzzese JL. Bcl-2 and p53 expression in resectable pancreatic adenocarcinomas: association with clinical outcome. Cancer Res 1996;2:2015-22.